Roche’s Phase II/III Skyscraper-06 Study of Tiragolumab Plus Tecentriq & Chemotherapy

Roche’s Phase II/III Skyscraper-06 Study of Tiragolumab Plus Tecentriq & Chemotherapy

By, Admin 5 July 2024

Roche’s phase II/III SKYSCRAPER-06 study of tiragolumab plus Tecentriq & chemotherapy in metastatic non-squamous NSCLC fails to meet primary endpoints

Overview

Roche announced that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature.

Combo of Tiragolumab Plus Tecentriq

  • The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes the phase II and phase III cohorts. 
  • The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. 
  • Based on these results, patients and investigators will be unblinded and we intend to halt the study. 
  • A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting.

From the CMO: Roche

  • These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of global product development. 
  • We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.

Phase III studies

  • Ongoing phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. 
  • Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab programme.

SKYSCRAPER-06

  • SKYSCRAPER-06 is a global phase II/III, randomised, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non- small cell lung cancer. 
  • Primary endpoints are overall survival (OS) and progression-free survival (PFS).

About Tiragolumab

  • Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. 
  • Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. 
  • Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq (atezolizumab). 
  • The TIGIT pathway is distinct but complementary to the PD-L1/PD-1 pathway. 
  • Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response.

Tecentriq Approvals

  • Tecentriq is a cancer immunotherapy approved for some of the most aggressive and difficult-to-treat forms of cancer. 
  • Tecentriq was the first cancer immunotherapy approved for the treatment of a certain type of early-stage (adjuvant) non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). 
  • Tecentriq is also approved in countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, certain types of metastatic urothelial cancer (mUC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma and alveolar soft part sarcoma (ASPS).

About Tecentriq

  • Tecentriq is a monoclonal antibody designed to bind with a protein called programmed death ligand-1 (PD-L1), which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. 
  • By inhibiting PD-L1, Tecentriq may enable the activation of T-cells. 
  • Tecentriq is a cancer immunotherapy that has the potential to be used as a foundational combination partner with other immunotherapies, targeted therapies and various chemotherapies across a broad range of cancers.

In addition to intravenous infusion, Tecentriq has been approved as a subcutaneous formulation in over 40 countries. The approved indications for Tecentriq SC mirror those of Tecentriq IV.

 

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!